PURPOSE: (18)F-Florbetapir (AV-45/Amyvid) is a novel positron emission tomography (PET) tracer for imaging plaque pathology in Alzheimer's disease (AD), while PET images of fluorodeoxyglucose (FDG) for cerebral glucose metabolism can provide complementary information to amyloid plaque images for diagnosis of AD. The goal of this preliminary study was to investigate the perfusion-like property of relative cerebral blood flow estimates (R(1)) and summed early-phase AV-45 images [perfusion AV-45 (pAV-45)] and optimize the early time frame for pAV-45. METHODS: Dynamic AV-45 PET scans (0-180 min) were performed in seven subjects. pAV-45, late-phase AV-45, and FDG images were spatially normalized to the Montreal Neurological Institute template aided by individual MRI images, and the corresponding standardized uptake value ratio (SUVR) was computed. The R(1) images were derived from a simplified reference tissue model. Correlations between regional and voxelwise R(1) and the corresponding FDG images were calculated. An optimization of time frames of pAV-45 was conducted in terms of correlation to FDG images. The optimal early time frame was validated in a separate cohort. RESULTS: The regional distribution in the R(1) images correlated well (R = 0.91) to that of the FDG within subjects. Consistently high correlation was noted across a long range of time frames. The maximal correlation of pAV-45 to FDG SUVR of R = 0.95 was observed at the time frame of 1-6 min, while the peak correlation of R = 0.99 happened at 0-2 min between pAV-45 and R(1). A similar result was achieved in the validation cohort. CONCLUSION: Preliminary results showed that the distribution patterns of R(1) and pAV-45 images are highly correlated with normalized FDG images, and the initial 5-min early time frame of 1-6 min is potentially useful in providing complementary FDG-like information to the amyloid plaque density by late-phase AV-45 images.
PURPOSE: (18)F-Florbetapir (AV-45/Amyvid) is a novel positron emission tomography (PET) tracer for imaging plaque pathology in Alzheimer's disease (AD), while PET images of fluorodeoxyglucose (FDG) for cerebral glucose metabolism can provide complementary information to amyloid plaque images for diagnosis of AD. The goal of this preliminary study was to investigate the perfusion-like property of relative cerebral blood flow estimates (R(1)) and summed early-phase AV-45 images [perfusion AV-45 (pAV-45)] and optimize the early time frame for pAV-45. METHODS: Dynamic AV-45 PET scans (0-180 min) were performed in seven subjects. pAV-45, late-phase AV-45, and FDG images were spatially normalized to the Montreal Neurological Institute template aided by individual MRI images, and the corresponding standardized uptake value ratio (SUVR) was computed. The R(1) images were derived from a simplified reference tissue model. Correlations between regional and voxelwise R(1) and the corresponding FDG images were calculated. An optimization of time frames of pAV-45 was conducted in terms of correlation to FDG images. The optimal early time frame was validated in a separate cohort. RESULTS: The regional distribution in the R(1) images correlated well (R = 0.91) to that of the FDG within subjects. Consistently high correlation was noted across a long range of time frames. The maximal correlation of pAV-45 to FDG SUVR of R = 0.95 was observed at the time frame of 1-6 min, while the peak correlation of R = 0.99 happened at 0-2 min between pAV-45 and R(1). A similar result was achieved in the validation cohort. CONCLUSION: Preliminary results showed that the distribution patterns of R(1) and pAV-45 images are highly correlated with normalized FDG images, and the initial 5-min early time frame of 1-6 min is potentially useful in providing complementary FDG-like information to the amyloid plaque density by late-phase AV-45 images.
Authors: N M Kemppainen; S Aalto; I A Wilson; K Någren; S Helin; A Brück; V Oikonen; M Kailajärvi; M Scheinin; M Viitanen; R Parkkola; J O Rinne Journal: Neurology Date: 2006-09-13 Impact factor: 9.910
Authors: Steven Ng; Victor L Villemagne; Sam Berlangieri; Sze-Ting Lee; Martin Cherk; Sylvia J Gong; Uwe Ackermann; Tim Saunder; Henri Tochon-Danguy; Gareth Jones; Clare Smith; Graeme O'Keefe; Colin L Masters; Christopher C Rowe Journal: J Nucl Med Date: 2007-04 Impact factor: 10.057
Authors: Philipp T Meyer; Sabine Hellwig; Florian Amtage; Christof Rottenburger; Ursula Sahm; Peter Reuland; Wolfgang A Weber; Michael Hüll Journal: J Nucl Med Date: 2011-02-14 Impact factor: 10.057
Authors: Valerie Treyer; Johannes Streffer; Matthias T Wyss; Andrea Bettio; Simon M Ametamey; Uta Fischer; Mark Schmidt; Fabrizio Gasparini; Christoph Hock; Alfred Buck Journal: J Nucl Med Date: 2007-06-15 Impact factor: 10.057
Authors: Seok Rye Choi; Geoff Golding; Zhiping Zhuang; Wei Zhang; Nathaniel Lim; Franz Hefti; Tyler E Benedum; Michael R Kilbourn; Daniel Skovronsky; Hank F Kung Journal: J Nucl Med Date: 2009-10-16 Impact factor: 10.057
Authors: Nicolaas P L G Verhoeff; Alan A Wilson; Shinichiro Takeshita; Liat Trop; Doug Hussey; Kernjit Singh; Hank F Kung; Mei-Ping Kung; Sylvain Houle Journal: Am J Geriatr Psychiatry Date: 2004 Nov-Dec Impact factor: 4.105
Authors: Ching-yee Oliver Wong; Joseph Thie; Marianne Gaskill; Richard Ponto; Jack Hill; Hai-yan Tian; Helena Balon; Dafang Wu; Darlene Fink-Bennett; Conrad Nagle Journal: BMC Nucl Med Date: 2006-07-12
Authors: Gunnar Blomquist; Henry Engler; Agneta Nordberg; Anna Ringheim; Anders Wall; Anton Forsberg; Sergio Estrada; Pernilla Frändberg; Gunnar Antoni; Bengt Långström Journal: Open Neuroimag J Date: 2008-11-13
Authors: Noble George; Emily G Gean; Ayon Nandi; Boris Frolov; Eram Zaidi; Ho Lee; James R Brašić; Dean F Wong Journal: CNS Drugs Date: 2015-04 Impact factor: 5.749